Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Sunitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 16 Apr 2012 Actual patient number 37 added as reported by ClinicalTrials.gov.